市場調査レポート

商品コード

細菌性膣炎治療薬の市場規模と予測（2021年～2031年）、世界・地域のシェア、動向、成長機会分析：タイプ別、投与経路別、剤形別、流通チャネル別、地域別

Bacterial Vaginosis Drug Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Route of Administration, Dosage Form, Distribution Channel, and Geography

出版日: 2025年02月03日
発行: The Insight Partners
ページ情報: 英文 184 Pages
納期: 即納可能

価格

PDF (Single User License)

USD 4,450 638,886円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 6,450 926,026円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 8,450 1,213,166円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

最新調査レポート「細菌性膣炎治療薬の2031年までの市場予測：タイプ別、投与経路別、剤形別、流通チャネル別、地域別の世界分析」によると、同市場は2024年の21億5,000万米ドルから成長し、2031年までには38億2,000万米ドルに達すると予測されており、2024年から2031年にかけてCAGR8.3%を記録すると予測されています。細菌性膣炎の市場開拓が進んでいること、新規の標的治療薬の開発に重点が置かれていることが、細菌性膣炎治療薬市場規模の拡大に寄与しています。しかし、高い再発率と治療アドヒアランスの課題が細菌性膣炎治療薬市場の成長を妨げています。さらに、マイクロバイオーム療法やプロバイオティクスへの傾倒の高まりは、今後数年間で新しい細菌性膣炎治療薬市場の動向をもたらすと予想されます。

収益では、北米が2024年の市場を独占しました。予測期間中も世界市場を独占すると予測されます。米国は世界最大の細菌性膣炎治療薬市場です。米国では、BVの有病率の増加、女性の健康に対する意識の高まり、革新的な治療法の開発への継続的な取り組みにより、細菌性膣炎治療薬市場が大きな成長を遂げています。BVは女性に最も多い膣感染症のひとつで、特に生殖年齢に影響を及ぼします。2024年のMedscapeの報告によると、米国の成人女性の約3分の1、すなわち約2,200万人の女性が毎年BVに罹患しており、1,000万人の女性が異常な膣分泌物のためにクリニックを訪れています。BVはしばしば性行為、ダウジング、ホルモンの変化などの要因と関連していますが、BVの正確な原因については不明な点が多いです。BVの主な治療法としては、米国食品医薬品局（FDA）に認可されているメトロニダゾールやクリンダマイシンなどの抗生物質があります。メトロニダゾールは経口剤と外用剤があり、BVの第一選択薬とされています。クリンダマイシンも経口剤と外用剤の両方が一般的です。プロバイオティクスやファージ療法などの新しい薬剤や製剤も、膣内細菌叢の自然な回復を助け、BVの再発を抑えるために登場してきています。

米国における政府の取り組みは、国民に膣炎に対する意識を高め、広める上で重要な役割を果たしています。国立衛生研究所（NIH）は、BVの原因、治療、予防に関する研究に資金を提供しています。NIHの努力により、マイクロバイオームとBVの原因におけるその役割についての理解が深まり、より的を絞った治療法の開発に不可欠なものとなっています。米国疾病予防管理センター（CDC）は、BVの診断と管理を改善するためのガイドラインと勧告を提供しています。これらの取り組みは、治療を標準化し、患者が最も効果的な治療を受けられるようにするのに役立ちます。さらに、国立小児保健・人間発達研究所（NICHD、連邦政府機関）とNIHは、BVを理解し、その原因と予防について女性を教育することに専念しています。NICHDは、BVに関連するリスクとその予防・治療法に関する研究に資金を提供し、実施しています。

細菌性膣炎治療薬の市場分析

将来の市場機会を提供する市場プレイヤーの戦略的イニシアティブ

細菌性膣炎治療薬市場で事業を展開する企業は、製品承認、提携、資金調達、契約、新製品発売などの戦略的開拓に絶えず注力しており、これらの戦略的開拓は、売上の向上、地理的リーチの拡大、既存顧客ベースよりも多くの顧客に対応するための能力強化に役立っています。細菌性膣炎治療薬市場で事業を展開する主要企業による戦略的イニシアチブを以下にいくつか紹介します。

2024年11月、Freya Biosciencesはビル＆メリンダ・ゲイツ財団から1,040万米ドルの戦略的投資を受け、現在の出資者であるデンマーク輸出投資基金（EIFO）から140万米ドルの追加融資を受けました。企業はこれらの資金を、早産のリスクや妊産婦と新生児の健康に影響を及ぼす可能性のあるその他の適応症に対処するためのBV治療用微生物免疫療法の開発に充てる予定です。

2022年3月、OrganonとDare Bioscience, Inc.は、OrganonがXACIATO（クリンダマイシンリン酸塩膣ゲル、2％）の全世界における権利をライセンスする契約を締結しました。これにより、XACIATOは細菌性膣炎の治療薬として米国食品医薬品局（FDA）から適格感染症製品（QIDP）とファスト・トラックの両方の指定を受けました。

2022年2月、Lupin Pharmaceuticals Inc.は、ソロセック（一般名：セクニダゾール）を12歳以上の女性患者におけるBV治療薬として使用するための追加新薬承認申請（sNDA）をFDAより取得しました。

2021年12月、FDAはDare Bioscience, Inc.製のXACIATO（クリンダマイシンリン酸塩膣ゲル、2％）を12歳以上の女性における細菌性膣炎の治療薬として承認しました。

2021年2月、Rebiotix（Ferring）とMyBioticsは、生殖医療と妊産婦の健康への応用を目的とした生きた微生物ベースの治療薬の開発で提携しました。この共同研究は、流産や妊娠・不妊症の合併症のリスク上昇に関連する可能性のある、出産適齢期の女性の細菌性膣炎に対する生きた微生物叢ベースの生物治療薬の創出を目的としています。

したがって、継続的な資金調達、製品の上市と承認、共同研究は、今後数年間の細菌性膣炎治療薬市場の成長に十分な機会を創出すると期待されています。

細菌性膣炎治療薬市場レポートセグメンテーション分析

細菌性膣炎治療薬市場の分析に貢献した主要セグメントは、タイプ、投与経路、剤形、流通チャネルです。

タイプに基づき、細菌性膣炎治療薬市場は処方薬と市販薬に区分されます。2024年の市場では、処方薬セグメントが大きなシェアを占めました。

投与経路では、細菌性膣炎治療薬市場は経口剤、膣剤、局所剤に分類されます。2024年には経口剤セグメントが市場を独占しました。

剤形では、細菌性膣炎治療薬市場は錠剤、クリーム、ゲル、溶液/洗浄剤、その他に分類されます。2024年には錠剤セグメントが市場を独占しました。

流通チャネルでは、細菌性膣炎治療薬市場は病院薬局、オンライン薬局、小売薬局に分類されます。2024年には病院薬局セグメントが市場を独占しました。

細菌性膣炎治療薬市場：競合情勢と主な発展

Bayer AG、Pfizer Inc、Sanofi SA、Starpharma Holdings Limited、Viatris Inc、Glenmark Pharmaceuticals Ltd、Lupin Ltd、Sun Pharmaceutical Industries Ltd、Organon &Co、Duchesnay Inc.（カナダ）などが細菌性膣炎治療薬市場で事業を展開する主要企業です。

European Journal of Obstetrics &Gynecology and Reproductive Biology、National Institutes of Health、Medscape、Government of Canada、UN World Population Prospects 2024、Eurostat、European Commission、Australian Government's Department of Health and Aged Care、World Bank、International Trade Administrationなどは、細菌性膣炎治療薬市場レポート作成時に参照した一次情報および二次情報です。

細菌性膣炎治療薬市場-主な市場力学
市場促進要因
- 細菌性膣炎の有病率の上昇
- 新規治療薬と標的治療薬の開発への注目の高まり
市場抑制要因
- 高い再発率と治療アドヒアランスの課題
市場機会
- 市場プレイヤーの戦略的取り組み
今後の動向
- マイクロバイオーム治療とプロバイオティクスへの関心の高まり
促進要因と抑制要因の影響

第6章細菌性膣炎治療薬の世界市場分析

細菌性膣炎治療薬の市場収益、2021年～2031年
細菌性膣炎治療薬の市場予測分析

第7章細菌性膣炎治療薬の市場分析-タイプ別

処方薬（Rx）
市販薬（OTC）

第8章細菌性膣炎治療薬の市場分析-投与経路別

経口
膣
局所

第9章細菌性膣炎治療薬の市場分析-剤形別

錠剤
クリーム
ゲル
溶液または洗浄剤
その他

第10章細菌性膣炎治療薬の市場分析-流通チャネル別

病院薬局
オンライン薬局
小売薬局

第11章細菌性膣炎治療薬市場-地域別分析

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- フランス
- スペイン
- イタリア
- その他欧州
アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- その他アジア太平洋
中東・アフリカ
- サウジアラビア
- 南アフリカ
- アラブ首長国連邦
- その他中東・アフリカ
中南米
- ブラジル
- アルゼンチン
- その他中南米

第12章業界情勢

細菌性膣炎治療薬市場における成長戦略
有機的成長戦略
無機的成長戦略

第13章企業プロファイル

Bayer AG
Pfizer Inc
Sanofi SA
Starpharma Holdings Limited
Viatris Inc
Glenmark Pharmaceuticals Ltd
Lupin Ltd
Sun Pharmaceutical Industries Ltd
Organon & Co
Duchesnay Inc., Canada

第14章付録

図表

List Of Tables

Table 1. Bacterial Vaginosis Drug Market Segmentation
Table 2. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Type
Table 3. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Route of Administration
Table 4. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Dosage Form
Table 5. Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
Table 6. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 7. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 8. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 9. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 10. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
Table 11. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 12. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 13. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 14. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 15. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 16. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 17. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 18. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 19. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 20. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 21. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 22. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 23. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 24. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 25. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 26. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 27. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
Table 28. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 29. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 30. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 31. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 32. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 33. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 34. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 35. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 36. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 37. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 38. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 39. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 40. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 41. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 42. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 43. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 44. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 45. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 46. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 47. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 48. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 49. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 50. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 51. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 52. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 53. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 54. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 55. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 56. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
Table 57. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 58. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 59. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 60. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 61. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 62. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 63. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 64. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 65. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 66. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 67. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 68. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 69. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 70. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 71. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 72. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 73. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 74. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 75. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 76. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 77. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 78. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 79. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 80. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 81. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 82. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 83. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 84. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 85. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
Table 86. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 87. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 88. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 89. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 90. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 91. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 92. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 93. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 94. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 95. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 96. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 97. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 98. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 99. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 100. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 101. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 102. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 103. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 104. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 105. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 106. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Country
Table 107. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 108. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 109. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 110. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 111. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 112. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 113. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 114. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 115. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Type
Table 116. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Route of Administration
Table 117. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Dosage Form
Table 118. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
Table 119. Recent Organic Growth Strategies in the Bacterial Vaginosis Drug Market
Table 120. Recent Inorganic Growth Strategies in the Bacterial Vaginosis Drug Market
Table 121. Glossary of Terms

List Of Figures

Figure 1. Bacterial Vaginosis Drug Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Bacterial Vaginosis Drug Market Revenue (US$ Million), 2021-2031
Figure 5. Bacterial Vaginosis Drug Market Share (%) - by Type (2024 and 2031)
Figure 6. Prescription Drugs (Rx): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Over-the-counter Drugs (OTC): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Bacterial Vaginosis Drug Market Share (%) - by Route of Administration (2024 and 2031)
Figure 9. Oral: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. Vaginal: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. Topical: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Bacterial Vaginosis Drug Market Share (%) - by Dosage Form (2024 and 2031)
Figure 13. Pills: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Creams: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Gel: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 16. Solution or Washes: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Others: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Bacterial Vaginosis Drug Market Share (%) - by Distribution Channel (2024 and 2031)
Figure 19. Hospital Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Online Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Retail Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 23. North America: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 24. United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 25. Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 26. Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 27. Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 28. Europe: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 29. Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 30. United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 31. France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 32. Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 33. Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 34. Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 35. Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 36. Asia Pacific: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 37. China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 38. Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 39. India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 40. Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 41. South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 42. Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 43. Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 44. Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 45. Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 46. South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 47. United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 48. Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 49. South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 50. South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 51. Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 52. Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 53. Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031(US$ Million)
Figure 54. Growth Strategies in the Bacterial Vaginosis Drug Market

Product Code: TIPRE00018820

According to our new research study on "Bacterial Vaginosis Drug Market Forecast to 2031 -Global Analysis - by Type, Route of Administration, Dosage Form, and Distribution Channel, and Geography," the market is anticipated to grow from US$ 2.15 billion in 2024 and is projected to reach US$ 3.82 billion by 2031; it is expected to register a CAGR of 8.3% during 2024-2031. Rising prevalence of bacterial vaginosis, and the increased focus on developing novel and targeted therapies are contributing to the growing Bacterial Vaginosis Drug market size. However, the high recurrence rate and treatment adherence challenges hampers the Bacterial Vaginosis Drug market growth. Further, rising inclination toward microbiome therapies and probiotics are expected to bring in new Bacterial Vaginosis Drug market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for bacterial vaginosis drugs in the world. In the US, the bacterial vaginosis drug market is experiencing significant growth due to the increasing prevalence of BV, rising awareness about women's health, and ongoing efforts for the development of innovative treatments. BV is one of the most common vaginal infections in women, particularly affecting those of reproductive age. According to a report by Medscape in 2024, approximately one-third of adult women in the US, i.e., ~22 million females, are affected by BV annually, and 10 million women visit clinics for abnormal vaginal discharge. It is often linked to factors such as sexual activity, douching, and hormonal changes; nonetheless, there is uncertainty around the exact causes of BV. The primary therapeutic options available for treating BV include antibiotics approved by the US Food and Drug Administration (FDA), such as metronidazole and clindamycin. Metronidazole, often available in oral and topical forms, is considered the first-line treatment for BV. Clindamycin is also commonly available in both oral and topical formulations. Newer drugs and formulations, such as probiotics and phage therapy, are also emerging to help restore the natural vaginal flora, thereby reducing the recurrence of BV.

Government initiatives in the US play a key role in creating and spreading awareness about vaginosis in the population. The National Institutes of Health (NIH) funds research into the causes, treatment, and prevention of BV. The NIH's efforts have led to a deeper understanding of the microbiome and its role in causing BV, which is crucial for developing more targeted therapies. Centers for Disease Control and Prevention (CDC) provide guidelines and recommendations to improve the diagnosis and management of BV. These initiatives help standardize care and ensure that patients receive the most effective treatment. Additionally, the National Institute of Child Health and Human Development (NICHD, a federal agency) and NIH are dedicated to understanding BV and educating women about its causes and prevention. NICHD funds and conducts research on the risks associated with BV and methods for its prevention and treatment.

Bacterial Vaginosis Drug Market Analysis

Strategic Initiatives by Market Players to Provide Market Opportunities in Future

Companies operating in the bacterial vaginosis drugs market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and reinforce their capacities to cater to a greater than existing customer base. A few strategic initiatives by key players operating in the bacterial vaginosis drugs market are mentioned below.

In November 2024, Freya Biosciences received US$ 10.4 million in strategic investment from the Bill & Melinda Gates Foundation, with US$ 1.4 million in additional financing from the current investor-Export and Investment Fund of Denmark (EIFO). The company plans to use these funds to develop microbial immunotherapies for the treatment of BV to address the risk of preterm birth along with other indications potentially affecting maternal and newborn health.

In March 2022, Organon and Dare Bioscience, Inc. entered into an agreement whereby Organon will license global rights to XACIATO (clindamycin phosphate vaginal gel, 2%). With this, XACIATO received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US Food and Drug Administration (FDA) for the treatment of bacterial vaginosis.

In February 2022, Lupin Pharmaceuticals Inc. received FDA approval for a supplemental New Drug Application (sNDA) to increase the use of SOLOSEC (secnidazole) for the treatment of BV among female patients aged 12 or older; the approval also entailed the treatment of trichomoniasis among patients from the said age group.

In December 2021, the FDA approved XACIATO (clindamycin phosphate vaginal gel, 2%) manufactured by Dare Bioscience, Inc. for the treatment of bacterial vaginosis in females of age 12 years or more.

In February 2021, Rebiotix (Ferring) and MyBiotics collaborated to develop live microbiome-based therapeutics for applications in reproductive medicine and maternal health. This collaboration aims to create live microbiota-based biotherapeutics for bacterial vaginosis among women of childbearing age, which may be associated with the increased risk of miscarriage and complications in pregnancy and fertility.

Therefore, ongoing funding, product launches and approvals, and collaborations are expected to create ample opportunities for the growth of the bacterial vaginosis drugs market in the coming years.

Bacterial Vaginosis Drug Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Bacterial Vaginosis Drug market analysis are type, route of administration, dosage form, and distribution channel.

Based on type, the bacterial vaginosis drug market is segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment held a larger share of the market in 2024.

In terms of route of administration, the bacterial vaginosis drug market is categorized into oral, vaginal, and topical. The oral segment dominated the market in 2024.

In terms of dosage form, the bacterial vaginosis drug market is categorized into pills, creams, gels, solutions/washes, and others. The pills segment dominated the market in 2024.

In terms of distribution channel, the bacterial vaginosis drug market is categorized into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.

Bacterial Vaginosis Drug Market: Competitive Landscape and Key Developments

Bayer AG, Pfizer Inc, Sanofi SA, Starpharma Holdings Limited, Viatris Inc, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Sun Pharmaceutical Industries Ltd, Organon & Co, Duchesnay Inc., Canada are among the key companies operating in the Bacterial Vaginosis Drug market.

European Journal of Obstetrics & Gynecology and Reproductive Biology, National Institutes of Health, Medscape, Government of Canada, UN World Population Prospects 2024, Eurostat, European Commission, Australian Government's Department of Health and Aged Care, World Bank, and International Trade Administration are among the primary and secondary sources referred to while preparing the Bacterial Vaginosis Drug market report.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Bacterial Vaginosis Drug Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Incidence Rate: Bacterial Vaginosis

5. Bacterial Vaginosis Drug Market - Key Market Dynamics

5.1 Bacterial Vaginosis Drug Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Prevalence of Bacterial Vaginosis
- 5.2.2 Increased Focus on Developing Novel and Targeted Therapies
5.3 Market Restraints
- 5.3.1 High Recurrence Rate and Treatment Adherence Challenges
5.4 Market Opportunities
- 5.4.1 Strategic Initiatives by Market Players
5.5 Future Trends
- 5.5.1 Rising Inclination Toward Microbiome Therapies and Probiotics
5.6 Impact of Drivers and Restraints:

6. Bacterial Vaginosis Drug Market - Global Market Analysis

6.1 Bacterial Vaginosis Drug Market Revenue (US$ Million), 2021-2031
6.2 Bacterial Vaginosis Drug Market Forecast Analysis

7. Bacterial Vaginosis Drug Market Analysis - by Type

7.1 Prescription Drugs (Rx)
- 7.1.1 Overview
- 7.1.2 Prescription Drugs (Rx): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Over-the-counter Drugs (OTC)
- 7.2.1 Overview
- 7.2.2 Over-the-counter Drugs (OTC): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

8. Bacterial Vaginosis Drug Market Analysis - by Route of Administration

8.1 Oral
- 8.1.1 Overview
- 8.1.2 Oral: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Vaginal
- 8.2.1 Overview
- 8.2.2 Vaginal: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Topical
- 8.3.1 Overview
- 8.3.2 Topical: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

9. Bacterial Vaginosis Drug Market Analysis - by Dosage Form

9.1 Pills
- 9.1.1 Overview
- 9.1.2 Pills: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Creams
- 9.2.1 Overview
- 9.2.2 Creams: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Gel
- 9.3.1 Overview
- 9.3.2 Gel: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Solution or Washes
- 9.4.1 Overview
- 9.4.2 Solution or Washes: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
9.5 Others
- 9.5.1 Overview
- 9.5.2 Others: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

10. Bacterial Vaginosis Drug Market Analysis - by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Online Pharmacies
- 10.2.1 Overview
- 10.2.2 Online Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Retail Pharmacies
- 10.3.1 Overview
- 10.3.2 Retail Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

11. Bacterial Vaginosis Drug Market - Geographical Analysis

11.1 North America
- 11.1.1 North America Bacterial Vaginosis Drug Market Overview
- 11.1.2 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.1.2.1 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
  - 11.1.2.2 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
  - 11.1.2.3 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
  - 11.1.2.4 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.1.3 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
  - 11.1.3.1 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
  - 11.1.3.2 United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.2.1 United States: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.1.3.2.2 United States: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.1.3.2.3 United States: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.1.3.2.4 United States: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.1.3.3 Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.3.1 Canada: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.1.3.3.2 Canada: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.1.3.3.3 Canada: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.1.3.3.4 Canada: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.1.3.4 Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.4.1 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.1.3.4.2 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.1.3.4.3 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.1.3.4.4 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.2 Europe
- 11.2.1 Europe Bacterial Vaginosis Drug Market Overview
- 11.2.2 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.2.2.1 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
  - 11.2.2.2 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
  - 11.2.2.3 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
  - 11.2.2.4 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.2.3 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
  - 11.2.3.1 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
  - 11.2.3.2 Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.2.1 Germany: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.2.3.2.2 Germany: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.2.3.2.3 Germany: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.2.3.2.4 Germany: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.2.3.3 United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.3.1 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.2.3.3.2 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.2.3.3.3 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.2.3.3.4 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.2.3.4 France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.4.1 France: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.2.3.4.2 France: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.2.3.4.3 France: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.2.3.4.4 France: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.2.3.5 Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.5.1 Spain: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.2.3.5.2 Spain: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.2.3.5.3 Spain: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.2.3.5.4 Spain: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.2.3.6 Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.6.1 Italy: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.2.3.6.2 Italy: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.2.3.6.3 Italy: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.2.3.6.4 Italy: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.2.3.7 Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.7.1 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.2.3.7.2 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.2.3.7.3 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.2.3.7.4 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.3 Asia Pacific
- 11.3.1 Asia Pacific Bacterial Vaginosis Drug Market Overview
- 11.3.2 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.3.2.1 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
  - 11.3.2.2 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
  - 11.3.2.3 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
  - 11.3.2.4 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.3.3 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
  - 11.3.3.1 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
  - 11.3.3.2 China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.2.1 China: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.3.3.2.2 China: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.3.3.2.3 China: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.3.3.2.4 China: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.3.3.3 Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.3.1 Japan: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.3.3.3.2 Japan: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.3.3.3.3 Japan: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.3.3.3.4 Japan: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.3.3.4 India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.4.1 India: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.3.3.4.2 India: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.3.3.4.3 India: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.3.3.4.4 India: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.3.3.5 Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.5.1 Australia: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.3.3.5.2 Australia: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.3.3.5.3 Australia: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.3.3.5.4 Australia: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.3.3.6 South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.6.1 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.3.3.6.2 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.3.3.6.3 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.3.3.6.4 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.3.3.7 Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.7.1 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.3.3.7.2 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.3.3.7.3 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.3.3.7.4 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.4 Middle East and Africa
- 11.4.1 Middle East and Africa Bacterial Vaginosis Drug Market Overview
- 11.4.2 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.4.2.1 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
  - 11.4.2.2 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
  - 11.4.2.3 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
  - 11.4.2.4 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.4.3 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
  - 11.4.3.1 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
  - 11.4.3.2 Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.2.1 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.4.3.2.2 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.4.3.2.3 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.4.3.2.4 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.4.3.3 South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.3.1 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.4.3.3.2 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.4.3.3.3 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.4.3.3.4 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.4.3.4 United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.4.1 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.4.3.4.2 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.4.3.4.3 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.4.3.4.4 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.4.3.5 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.5.1 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.4.3.5.2 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.4.3.5.3 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.4.3.5.4 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
11.5 South and Central America
- 11.5.1 South and Central America Bacterial Vaginosis Drug Market Overview
- 11.5.2 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.5.2.1 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
  - 11.5.2.2 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
  - 11.5.2.3 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
  - 11.5.2.4 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.5.3 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
  - 11.5.3.1 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
  - 11.5.3.2 Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.2.1 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.5.3.2.2 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.5.3.2.3 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.5.3.2.4 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.5.3.3 Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.3.1 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.5.3.3.2 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.5.3.3.3 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.5.3.3.4 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
  - 11.5.3.4 Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.4.1 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Type
    - 11.5.3.4.2 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
    - 11.5.3.4.3 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
    - 11.5.3.4.4 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in the Bacterial Vaginosis Drug Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Bayer AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Pfizer Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Sanofi SA
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Starpharma Holdings Limited
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Viatris Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Glenmark Pharmaceuticals Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Lupin Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Sun Pharmaceutical Industries Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Organon & Co
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Duchesnay Inc., Canada
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms for Bacterial Vaginosis Drug Market

細菌性膣炎治療薬の市場規模と予測（2021年～2031年）、世界・地域のシェア、動向、成長機会分析：タイプ別、投与経路別、剤形別、流通チャネル別、地域別

Bacterial Vaginosis Drug Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Route of Administration, Dosage Form, Distribution Channel, and Geography

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章細菌性膣炎治療薬の市場情勢

第5章細菌性膣炎治療薬市場-主な市場力学

第6章細菌性膣炎治療薬の世界市場分析

第7章細菌性膣炎治療薬の市場分析-タイプ別

第8章細菌性膣炎治療薬の市場分析-投与経路別

第9章細菌性膣炎治療薬の市場分析-剤形別

第10章細菌性膣炎治療薬の市場分析-流通チャネル別

第11章細菌性膣炎治療薬市場-地域別分析

第12章業界情勢

第13章企業プロファイル

第14章付録

List Of Tables

List Of Figures

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Bacterial Vaginosis Drug Market Landscape

5. Bacterial Vaginosis Drug Market - Key Market Dynamics

6. Bacterial Vaginosis Drug Market - Global Market Analysis

7. Bacterial Vaginosis Drug Market Analysis - by Type

8. Bacterial Vaginosis Drug Market Analysis - by Route of Administration

9. Bacterial Vaginosis Drug Market Analysis - by Dosage Form

10. Bacterial Vaginosis Drug Market Analysis - by Distribution Channel

11. Bacterial Vaginosis Drug Market - Geographical Analysis

12. Industry Landscape

13. Company Profiles

14. Appendix

細菌性膣炎治療薬の市場規模と予測（2021年～2031年）、世界・地域のシェア、動向、成長機会分析：タイプ別、投与経路別、剤形別、流通チャネル別、地域別

Bacterial Vaginosis Drug Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Route of Administration, Dosage Form, Distribution Channel, and Geography

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 細菌性膣炎治療薬の市場情勢

第5章 細菌性膣炎治療薬市場-主な市場力学

第6章 細菌性膣炎治療薬の世界市場分析

第7章 細菌性膣炎治療薬の市場分析-タイプ別

第8章 細菌性膣炎治療薬の市場分析-投与経路別

第9章 細菌性膣炎治療薬の市場分析-剤形別

第10章 細菌性膣炎治療薬の市場分析-流通チャネル別

第11章 細菌性膣炎治療薬市場-地域別分析

第12章 業界情勢

第13章 企業プロファイル

第14章 付録

List Of Tables

List Of Figures

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Bacterial Vaginosis Drug Market Landscape

5. Bacterial Vaginosis Drug Market - Key Market Dynamics

6. Bacterial Vaginosis Drug Market - Global Market Analysis

7. Bacterial Vaginosis Drug Market Analysis - by Type

8. Bacterial Vaginosis Drug Market Analysis - by Route of Administration

9. Bacterial Vaginosis Drug Market Analysis - by Dosage Form

10. Bacterial Vaginosis Drug Market Analysis - by Distribution Channel

11. Bacterial Vaginosis Drug Market - Geographical Analysis

12. Industry Landscape

13. Company Profiles

14. Appendix

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章細菌性膣炎治療薬の市場情勢

第5章細菌性膣炎治療薬市場-主な市場力学

第6章細菌性膣炎治療薬の世界市場分析

第7章細菌性膣炎治療薬の市場分析-タイプ別

第8章細菌性膣炎治療薬の市場分析-投与経路別

第9章細菌性膣炎治療薬の市場分析-剤形別

第10章細菌性膣炎治療薬の市場分析-流通チャネル別

第11章細菌性膣炎治療薬市場-地域別分析

第12章業界情勢

第13章企業プロファイル

第14章付録